Prevention of Anthracycline-induced Cardiotoxicity
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Anthracycline based anti-tumoral therapies are know to develop cardiac damage that could also
lead to heart failure. Monocentric studies proved that a treatment with ACE inhibitors (ACEi)
and betablockers (BB) during the first elevation of cardiac troponin is able to reduce the
incidence of heart failure (HF).
ICOS-ONE trial is a multicenter randomized trial comparing two therapeutic strategies. The
main objective is to assess whether enalapril started concomitantly to AC-containing
treatments, can prevent cardiac toxicity more effectively than when enalapril is prescribed
to selected patients showing laboratory evidences of injury after chemotherapy, during
follow-up visits in 268 patients.